These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12974100)

  • 21. Toward the development of prophylactic and therapeutic human papillomavirus type-16 lipopeptide vaccines.
    Moyle PM; Olive C; Ho MF; Pandey M; Dyer J; Suhrbier A; Fujita Y; Toth I
    J Med Chem; 2007 Sep; 50(19):4721-7. PubMed ID: 17705361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategies for human papillomavirus therapeutic vaccines and other therapies based on the E6 and E7 oncogenes.
    Govan VA
    Ann N Y Acad Sci; 2005 Nov; 1056():328-43. PubMed ID: 16387699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection.
    Brulet JM; Maudoux F; Thomas S; Thielemans K; Burny A; Leo O; Bex F; Hallez S
    Eur J Immunol; 2007 Feb; 37(2):376-84. PubMed ID: 17274002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
    Davidson EJ; Boswell CM; Sehr P; Pawlita M; Tomlinson AE; McVey RJ; Dobson J; Roberts JS; Hickling J; Kitchener HC; Stern PL
    Cancer Res; 2003 Sep; 63(18):6032-41. PubMed ID: 14522932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use.
    Koido S; Nikrui N; Ohana M; Xia J; Tanaka Y; Liu C; Durfee JK; Lerner A; Gong J
    Gynecol Oncol; 2005 Nov; 99(2):462-71. PubMed ID: 16137749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy.
    Li Y; Subjeck J; Yang G; Repasky E; Wang XY
    Vaccine; 2006 Jun; 24(25):5360-70. PubMed ID: 16714072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human papillomavirus infection: an old disease, a new vaccine.
    Giles M; Garland S
    Aust N Z J Obstet Gynaecol; 2006 Jun; 46(3):180-5. PubMed ID: 16704468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-tumor immune responses.
    Du YC; Lin P; Zhang J; Lu YR; Ning QZ; Wang Q
    Tissue Antigens; 2006 May; 67(5):368-76. PubMed ID: 16671943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can genital-tract human papillomavirus infection and cervical cancer be prevented with a vaccine?
    Dillner J; Brown DR
    Expert Rev Mol Med; 2004 Apr; 6(9):1-21. PubMed ID: 15096282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Vaccination against cervical cancer and diseases caused by Human Papillomavirus].
    Bornstein J; Tuma R; Zarfati D; Ophir E
    Harefuah; 2007 Oct; 146(10):764-9, 814. PubMed ID: 17990391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer.
    Kao JY; Zhang M; Chen CM; Chen JJ
    Immunol Lett; 2005 Nov; 101(2):154-9. PubMed ID: 15993950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toward vaccines against cervical cancer.
    Jansen KU
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):228-32. PubMed ID: 15603257
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
    Hantz S; Alain S; Denis F
    Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Killing activity of cytotoxic T lymphocytes stimulated by dendritic cell vaccine loaded with autologous cervical cancer antigen].
    Zhou CJ; Ma W; Zhou JD; Zhao YX; Xie HQ
    Ai Zheng; 2006 Feb; 25(2):143-7. PubMed ID: 16480575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Vaccination against human papillomavirus for the prevention of cervical cancer].
    Quint WG; ter Harmsel WA; van Doorn LJ
    Ned Tijdschr Geneeskd; 2006 Jun; 150(25):1380-4. PubMed ID: 16841585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preventive and therapeutic HPV vaccines.
    Monie A; Hung CF; Wu TC
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1038-50. PubMed ID: 18058574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments.
    Kang TH; Lee JH; Bae HC; Noh KH; Kim JH; Song CK; Shin BC; Hung CF; Wu TC; Park JS; Kim TW
    Immunol Lett; 2006 Aug; 106(2):126-34. PubMed ID: 16844231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice.
    Gomez-Gutierrez JG; Elpek KG; Montes de Oca-Luna R; Shirwan H; Sam Zhou H; McMasters KM
    Cancer Immunol Immunother; 2007 Jul; 56(7):997-1007. PubMed ID: 17146630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
    David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
    Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system.
    Berraondo P; Nouzé C; Préville X; Ladant D; Leclerc C
    Cancer Res; 2007 Sep; 67(18):8847-55. PubMed ID: 17875726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.